Φορτώνει......
Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth
BACKGROUND: Increased exposure to multitargeted kinase inhibitor sunitinib is associated with improved outcome, emphasizing the importance of maintaining adequate dosing and drug levels. The currently approved schedule (50 mg daily, four weeks on, two weeks off) precludes further dose-intensificatio...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | J Exp Clin Cancer Res |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
BioMed Central
2016
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5013589/ https://ncbi.nlm.nih.gov/pubmed/27604186 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-016-0411-2 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|